| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 06/27/2013 | WO2013096899A2 Stable formulations for cns delivery of arylsulfatase a |
| 06/27/2013 | WO2013096868A2 Saposin-a derived peptides and uses thereof |
| 06/27/2013 | WO2013096847A1 Serum amyloid p-antibody fusion proteins |
| 06/27/2013 | WO2013096837A1 Methods for modulating metastasis-associated-in-lung-adenocarcinoma-transcript-1(malat-1) expression |
| 06/27/2013 | WO2013096829A2 Activation of cellular assault processes in the treatment of glioblastoma multiforme |
| 06/27/2013 | WO2013096793A1 Gain-of-function adamts13 variants resistant to autoantibody inhibition and methods of use thereof |
| 06/27/2013 | WO2013096791A1 Process for making high concentration protein formulations |
| 06/27/2013 | WO2013096755A1 Proteolytically resistant hydrogen bond surrogate helices |
| 06/27/2013 | WO2013096723A1 A method for hair growth using granulocyte-colony stimulating factor |
| 06/27/2013 | WO2013096458A1 Recombinant human alpha-1-antitrypsin for the treatment of inflammatory disorders |
| 06/27/2013 | WO2013096423A1 Combination therapy with interferon and andrographolides for multiple sclerosis |
| 06/27/2013 | WO2013096386A1 Ctp-based insulin analogs for treatment of diabetes |
| 06/27/2013 | WO2013096335A1 Administration of an antagonist of alpha 5 beta 1 for anti-antiogenesis and cancer treatment |
| 06/27/2013 | WO2013096000A1 Protease enzymes for increased protein digestion rate and absorption and methods of using the same |
| 06/27/2013 | WO2013095973A1 Hdc-sign binding peptides |
| 06/27/2013 | WO2013095903A1 Novel gh-rh analogs with potent agonistic effects |
| 06/27/2013 | WO2013094992A2 Use of growth factor for regenerating damaged periodontal tissue and pulp tissue of extracted tooth, composition containing said growth factor as active ingredient, and kit for tissue regeneration |
| 06/27/2013 | WO2013094697A1 Anti-tumor peptide and use therefor |
| 06/27/2013 | WO2013094250A1 Bifidobacterium proliferation promoter |
| 06/27/2013 | WO2013093878A1 A conditioned medium obtained from placental mesenchymal stem cells and use thereof in the therapeutic treatment of preeclampsia |
| 06/27/2013 | WO2013093720A2 Anti-diabetic compounds |
| 06/27/2013 | WO2013093514A2 Vaccines - peptides |
| 06/27/2013 | WO2013093489A2 Detection and treatment of breast cancer |
| 06/27/2013 | WO2013093045A2 Cyclotides as immunosuppressive agents |
| 06/27/2013 | WO2013093039A1 Peptides targeting receptor activator of nuclear factor -kappa b (rank) and their applications |
| 06/27/2013 | WO2013093027A1 Use of c1-inhibitor for the treatment of secondary edema of the central nervous system |
| 06/27/2013 | WO2013093009A1 N -terminally modified insulin derivatives |
| 06/27/2013 | WO2013092851A1 Process for obtaining rice protein hydrolysates useful in the prevention and/or treatment of obesity |
| 06/27/2013 | WO2013092776A1 Novel prongf mutants and uses thereof in the production of beta-ngf |
| 06/27/2013 | WO2013092703A2 Glucagon analogues |
| 06/27/2013 | WO2013092672A2 Method for recombinant production of labyrinthopeptins and functional derivatives thereof |
| 06/27/2013 | WO2013092640A1 Optineurin-derived polypeptides, their nucleic acids and uses thereof |
| 06/27/2013 | WO2013092558A1 Preparations containing amorphous emodepside |
| 06/27/2013 | WO2013092475A1 Crystals of glucokinase regulatory protein (gkrp) |
| 06/27/2013 | WO2013092212A1 Peptidic inhibitor of signal transmission from g-alpha-s to g-alpha-i-coupled receptor cascades |
| 06/27/2013 | WO2013091896A1 Novel jnk inhibitor molecules for treatment of various diseases |
| 06/27/2013 | WO2013091895A1 Novel method for the manufacturing of di-chain proteins for use in humans |
| 06/27/2013 | WO2013091883A2 Selective gpcr ligands |
| 06/27/2013 | WO2013091670A1 Novel jnk inhibitor molecules for treatment of various diseases |
| 06/27/2013 | WO2013091361A1 Cycloheptapeptide and use thereof in preparation of anti-tumour drugs |
| 06/27/2013 | WO2013091283A1 Pharmaceutical compositions of triptorelin microspheres |
| 06/27/2013 | WO2013091273A1 Method for producing wheat glutamine peptide |
| 06/27/2013 | WO2013091164A1 Small molecule polypeptide for preventing and restraining inflammation and application of same |
| 06/27/2013 | WO2013091071A1 Use of cyclic peptides from flaxseed for improving animal and human health |
| 06/27/2013 | WO2013091070A1 Cyclic peptide mixtures from flaxseed and uses thereof |
| 06/27/2013 | WO2013091008A1 Method of treating reduced ceruloplasmin functionality in the central nervous system |
| 06/27/2013 | WO2013091004A1 Prevention and treatment of mycobacterium infection |
| 06/27/2013 | WO2013090991A1 Tgf-beta therapy |
| 06/27/2013 | WO2013090978A1 Dosage regime for apolipoprotein formulations |
| 06/27/2013 | WO2013040564A3 Antibody recognizing arbitrarily designed epitope of three or more amino acid residues in a peptide and method of generating thereof |
| 06/27/2013 | WO2013040478A3 Hyr1-derived compositions and methods of treatment using same |
| 06/27/2013 | WO2013037504A4 Systems and methods for diminishing cell growth and inducing selective killing of target cells |
| 06/27/2013 | WO2013021346A3 A novel method for peroral delivery of insulin and its analogues for therapeutic usage |
| 06/27/2013 | WO2012164380A3 Dispersion and detachment of cell aggregates |
| 06/27/2013 | WO2012075549A8 Agents for increased resistance against oxidative stress conditions |
| 06/27/2013 | WO2012062930A9 Use of interleukin 10 mrna transfected macrophages in anti-inflammatory therapies |
| 06/27/2013 | WO2010077154A8 A method of producing a novel opioid peptide |
| 06/27/2013 | US20130165970 Bonding tissues and cross-linking proteins wth naphthalimide compounds |
| 06/27/2013 | US20130165634 Expression and export of angiogenesis inhibitors as immunofusins |
| 06/27/2013 | US20130165633 Endogenous and Non-Endogenous Versions of Human G Protein-Coupled Receptors |
| 06/27/2013 | US20130165503 Method for Treating Ocular Neovascularization |
| 06/27/2013 | US20130165393 Phospholipid and protein tablets |
| 06/27/2013 | US20130165392 Hepatocyte growth factor mimics as therapeutic agents |
| 06/27/2013 | US20130165391 B2-glycoprotein i peptide inhibitors |
| 06/27/2013 | US20130165388 Method of Producing a Paralytic Peptide |
| 06/27/2013 | US20130165387 Low frequency glatiramer acetate therapy |
| 06/27/2013 | US20130165384 Decellularized small particle tissue |
| 06/27/2013 | US20130165383 Apo-2 ligand/trail variants and uses thereof |
| 06/27/2013 | US20130165380 Administration of an antagonist of a5ß1 for anti-angiogenesis and cancer treatment |
| 06/27/2013 | US20130165379 Formulations of Exendins and Exendin Agonist Analogs |
| 06/27/2013 | US20130165378 Method of treating human growth hormone mediated condition |
| 06/27/2013 | US20130165377 Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions |
| 06/27/2013 | US20130165376 Heparin Binding Epidermal Growth Factor (HB-EGF) for Use in Methods of Treating and Preventing Intestinal Injury Related to Hemorrhagic Shock and Resuscitation |
| 06/27/2013 | US20130165375 Treatment of depressive disorders |
| 06/27/2013 | US20130165374 Prevention of allergy at weaning |
| 06/27/2013 | US20130165370 Counteracting Drug-Induced Obesity Using GLP-1 Agonists |
| 06/27/2013 | US20130165369 METHOD OF TREATING OBESITY AND METABOLIC DISORDERS RELATED TO EXCESS ADIPOSE TISSUE BY ADMINISTRATION OF sFRP-- PEPTIDE |
| 06/27/2013 | US20130165368 Antimicrobial compounds |
| 06/27/2013 | US20130164843 Method and medicament for inhibiting the expression of a given gene |
| 06/27/2013 | US20130164823 Expression System |
| 06/27/2013 | US20130164815 Process for the production of a reversibly inactive acidified plasmin composition |
| 06/27/2013 | US20130164721 Augmented cognitive training |
| 06/27/2013 | US20130164379 Nanoparticle micelle coated compositions |
| 06/27/2013 | US20130164377 Shell-and-core dosage form approaching zero-order drug release |
| 06/27/2013 | US20130164372 Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| 06/27/2013 | US20130164367 Treatment of neurodegenerative disease with creb-binding protein |
| 06/27/2013 | US20130164366 Method and medicament for inhibiting the expression of a given gene |
| 06/27/2013 | US20130164365 Formulations for treatment with glucosinolates |
| 06/27/2013 | US20130164363 Antimicrobial flush solutions |
| 06/27/2013 | US20130164340 Tropoelastins and uses thereof |
| 06/27/2013 | US20130164313 Dna sequence, and recombinant preparation of group 4 major allergens from cereals |
| 06/27/2013 | US20130164303 Combination preparation including a cytokine antagonist |
| 06/27/2013 | US20130164297 Modulation of activity of neurotrophins |
| 06/27/2013 | US20130164287 Soluble tumor necrosis factor receptor treatment of medical disorders |
| 06/27/2013 | US20130164284 Compositions and methods to treat bone related disorders |
| 06/27/2013 | US20130164283 Antibody induced cell membrane wounding |
| 06/27/2013 | US20130164276 AGENT FOR DYSFUNCTION DUE TO NEUROPATHY AND Rho KINASE ACTIVATION INHIBITOR |
| 06/27/2013 | US20130164275 Method for treating acidosis in ruminants |
| 06/27/2013 | US20130164273 Reversibly inactivated acidified plasmin composition |
| 06/27/2013 | US20130164267 Adipose tissue-derived stem cells for veterinary use |